The Color of Stem Cells
By Josef Tayag,
The Greenlining Institute
| 09. 09. 2005
Why the benefits of stem cell research might not be for people like me.
After losing half of one of my lungs to tuberculosis while
volunteering in the Andes last year, I assumed that life would
just never be the same again. By this I meant that the flight
of stairs to my apartment would always seem twice as long and
that I would have to give up things I enjoyed like taking long
runs on Sunday mornings.
However, the promise of therapeutic treatments derived from
stem cell research gives individuals like me a hope for normalcy.
Yet, as an immigrant from a low-income family, I can’t
stop from cringing at the thought that the low-income and marginalized
communities of the state still have no explicit guarantee of
access to the promised 'cures' of Prop. 71—much less to
adequate health care in general.
Last Friday, the Independent Citizen’s Oversight Committee
(ICOC) allocated a little over $39 million to prestigious research
institutions like UCLA, UC Berkeley, Stanford, USC, and Cal
Tech among others. Yet, it’s unclear from perusing through
many of their grant proposals just how much focus these research
institutions will give to communities...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...